tirzepatide in the news FDA approves new obesity drug from Eli Lilly named Zepbound Study: Tirzepatide produces greater weight

Baseline and periodic monitoringincluding fasting glucose, HbA1c, and IGF-1allows metabolic and hormonal effects to be caught early

Similarly to cell lines, primary embryonic MN cultures from SOD1 G93A ALS mice showed a diminished Nrf2 nuclear expression and downregulation of the enzymes involved in GSH biosynthesis, associated with increased susceptibility to Nerve Growth Factor (NGF)-induced apoptosis [257]

Tirzepatide is a once-weekly subcutaneous injectable peptide (approved by the Food and Drug Administration [FDA] for type 2 diabetes) engineered from the native GIP sequence, with agonist activity at both the GIP and GLP-1 receptors

Take Home For non-anesthesiologists providing sedation: Screen for GLP-1 use and symptoms

By identifying your genetic peptide pathway predispositions in your first month of treatment, PlexusDx personalizes your long-term treatment plan before spending months on a suboptimal approach